The Advanced Therapeutics for Alzheimer's Disease Review Board: A multidisciplinary model to facilitate safe access to amyloid-targeting therapies in general neurology across the Sutter Health system. (PubMed, Alzheimers Dement (Amst)) - Oct 11, 2026 - "Total amyloid-related imaging abnormality rate was 17.4% for lecanemab and 28.8% for donanemab. We describe a system-wide review board model that supported ATT prescribing by general neurologists and expanded safe access to ATTs across a large integrated health system."
Journal • Alzheimer's Disease • CNS Disorders
|
|
Armen J Moughamian; Austin Momii; Jean Minton; Lisamarie La Vallee; Michelle Manifield; Shawn Kile; Travis Urban
|